Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge

Supavit Chesdachai,Christina G. Rivera,Kristin C. Cole,Hilary R. Teaford,Maria L. Gonzalez Suarez,Jennifer J. Larsen,Ravindra Ganesh,Sidna Tulledge-Scheitel,Raymund R. Razonable

DOI: https://doi.org/10.1038/s41598-024-56195-y

IF: 4.6

2024-03-07

Scientific Reports

Abstract:Studies conducted prior to SARS-CoV-2 Omicron demonstrated that sotrovimab and remdesivir reduced hospitalization among high-risk outpatients with mild to moderate COVID-19. However, their effectiveness has not been directly compared. This study examined all high-risk outpatients with mild to moderate COVID-19 who received either remdesivir or sotrovimab at Mayo Clinic during the Omicron BA.1 surge from January to March 2022. COVID-19-related hospitalization or death within 28 days were compared between the two treatment groups. Among 3257 patients, 2158 received sotrovimab and 1099 received remdesivir. Patients treated with sotrovimab were younger and had lower comorbidity but were more likely to be immunocompromised than remdesivir-treated patients. The majority (89%) had received at least one dose of COVID-19 vaccine. COVID-19-related hospitalization (1.5% and 1.0% in remdesivir and sotrovimab, respectively, p = .15) and mortality within 28 days (0.4% in both groups, p = .82) were similarly low. A propensity score weighted analysis demonstrated no significant difference in the outcomes between the two groups. We demonstrated favorable outcomes that were not significantly different between patients treated with remdesivir or sotrovimab.

multidisciplinary sciences

What problem does this paper attempt to address?

The problem that this paper aims to solve is to evaluate the actual efficacy of two antiviral drugs - remdesivir and sotrovimab - in the treatment of high - risk mild - to - moderate COVID - 19 patients, and to compare the effects of these two drugs in preventing hospitalization and death.

### Research Background
- **Research Motivation**: During the prevalence of the SARS - CoV - 2 Omicron (Omicron) BA.1 variant, both remdesivir and sotrovimab were used to treat high - risk mild - to - moderate COVID - 19 patients. However, the effects of these two drugs have not been directly compared.
- **Research Purpose**: Through retrospective analysis, compare the actual efficacy of remdesivir and sotrovimab in preventing hospitalization and death in high - risk mild - to - moderate COVID - 19 patients.

### Research Methods
- **Research Design**: This is a retrospective study, including all high - risk mild - to - moderate COVID - 19 patients treated at the Mayo Clinic from January 1 to March 15, 2022.
- **Research Population**: A total of 3,257 patients, of which 2,158 received sotrovimab treatment and 1,099 received remdesivir treatment.
- **Primary Outcome Indicator**: The composite rate of COVID - 19 - related hospitalization or death within 28 days after treatment.
- **Statistical Analysis**: Use the propensity score (PS) weighting method to adjust for the imbalance of baseline characteristics, and then perform weighted logistic regression analysis to evaluate the association between treatment and hospitalization or death within 28 days.

### Main Findings
- **Baseline Characteristics**: Patients receiving sotrovimab treatment were younger, had fewer comorbidities, but were more likely to be in an immunosuppressed state.
- **Main Outcomes**:
- The hospitalization rate in the sotrovimab group was 1.0%, and that in the remdesivir group was 1.5% (p = 0.15).
- The 28 - day all - cause mortality rate in both groups was 0.4% (p = 0.82).
- Analysis after propensity score weighting showed that there was no significant difference in the COVID - 19 - related hospitalization or mortality rate within 28 days between the two groups (1.5% in the sotrovimab group vs. 1.6% in the remdesivir group, p = 0.79).

### Conclusions
- **Main Conclusion**: Despite differences in baseline characteristics, remdesivir and sotrovimab have similar actual efficacy in treating high - risk mild - to - moderate COVID - 19 patients and can effectively reduce the risk of hospitalization and death.
- **Clinical Significance**: This study provides an important reference for clinicians, indicating that in such patients, remdesivir and sotrovimab can be effective treatment options.

### Limitations
- **Decision - Influencing Factors**: The choice of drugs may be influenced by the joint decision - making of doctors and patients, and these factors are not fully included in the analysis.
- **Limited Number of Events**: The limited number of events in the study limits the feasibility of multivariate analysis.
- **Propensity Score Weighting**: Although propensity score weighting was used, it still failed to completely balance some baseline characteristics between the two groups.
- **Lack of Control Group**: There is no untreated control group in the study, making it difficult to evaluate the effect of each drug relative to no treatment.
- **Retrospective Study**: The retrospective nature of the study may make it difficult to identify potential confounding variables.

Through these findings, the researchers provide a valuable reference for the treatment options of high - risk mild - to - moderate COVID - 19 patients.